Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation

Liver Transplantation

Volumn 6, Issue 4, 2000, Pages 434-439

  Dodson, S Forrest ^a,b,c   De Vera, Michael E ^a,b,c   Bonham, C Andrew ^a,b,c   Geller, David A ^a,b,c   Rakela, Jorge ^a,b,c   Fung, John J ^a,b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; LAMIVUDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; INFECTION PREVENTION; LIVER TRANSPLANTATION; MALE; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; REINFECTION;

EID: 0033943922     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2000.6446     Document Type: Article

References (23)

1. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
2. Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunization
3. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients
4. Long-term passive immunoprophylaxis or B virus recurrence after liver transplantation in HB(s)antigen-positive patients
5. Liver transplantation in European patients with the hepatitis B surface antigen
6. Absence of initial viral replication and long-term high-dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation
7. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization
8. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization
9. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
10. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation
11. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
12. A preliminary trial of lamivudine for chronic hepatitis B infection
13. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
14. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
15. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
16. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
17. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
18. High pretreatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft reinfection after liver transplantation
19. Mercury toxicity (acrodynia) induced by long-term injection of gammaglobulin
20. Mercury poisoning associated with high-dose hepatitis B immune globulin administration after liver transplantation for chronic hepatitis B
21. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation
22. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
23. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin